Evaxion biotech presents paper on potential of deep data on immune complex stability to optimize cancer immunotherapy

Copenhagen, denmark, april 20, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by jens kringelum, phd, evaxion's director in genomic immuno-oncology, at the 4th neoantigen summit europe, being held virtually april 20-22, focusing on “ai in personalized cancer medicine”. the presentation described evaxion's recent improvement in determining cancer neoepitopes through measurement and prediction of peptide-mhc (pmhc) complex stability.
EVAX Ratings Summary
EVAX Quant Ranking